<DOC>
	<DOCNO>NCT00436670</DOCNO>
	<brief_summary>A Multi-center , Randomized , Placebo , Multi-Dose study evaluate efficacy AMG 317 compare placebo measure change Asthma Control Questionnaire ( ACQ ) symptom score baseline week 12 .</brief_summary>
	<brief_title>Phase II Study Evaluate Efficacy AMG 317</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Males females 18 65 year age time screen Baseline percent predict FEV1 ≥ 50 % ≤ 80 % screening At least 12 % reversibility baseline FEV1 beta agonist inhalation , demonstrate office document medical record within past 12 month Inhaled corticosteroid ( ICS ) ≥ 200 ≤ 1000 µg/day fluticasone equivalent . Stable ICS dose ≥ 30 day screen dose expect remain stable treatment investigational agent . Must use ICS least last 3 consecutive month screen If receive allergen immunotherapy , stable dose &gt; 3 month screen anticipated remain stable duration study Positive skin prick RAST Ongoing asthma symptom ACQ score screen baseline ≥ 1.5 point Nonsmoker exsmoker &lt; 10 packyears ( eg , 1 pack per day 10 year ) stop ≥ 1 year ago Acute asthma exacerbation require emergency room ( ER ) treatment hospitalization within 3 month History endotracheal intubation asthmarelated exacerbation within 3 year screen Respiratory illness within 4 week screen History chronic obstructive pulmonary disease ( COPD ) chronic pulmonary condition asthma Received longacting beta agonist , theophylline , inhaled anticholinergic , oral beta 2 agonist , cromolyn therapeutic within 1 week first runin visit . Leukotriene antagonists within 2 week first runin visit Oral parenteral corticosteroid within 6 week first runin visit Live/attenuated vaccination within 4 week screen study Any uncontrolled , clinically significant systemic disease ( eg , chronic renal failure , uncontrolled hypertension , liver disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergy</keyword>
	<keyword>IL-13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-4R</keyword>
</DOC>